case_images: PMC10904673_01
case_images: Photograph of the patient's neck-the arrow indicates the tumor mass in the IV and V regions of the neck.
case_images: CRIOT2024-8867131.001.jpg
case_images: PMC10904673_01_CRIOT2024-8867131.001.jpg
case_images: fig1
case_images: A 56-year-old patient was admitted to our clinic because of a tumefaction on his left side of his neck, which he noticed 6 months earlier and was gradually increasing (Figure 1).
case_images: Computerized tomography of the neck shows a large tumor mass on the left side. (a) Axial view (b) sagittal view (c) coronal view.
case_images: CRIOT2024-8867131.002.jpg
case_images: PMC10904673_01_CRIOT2024-8867131.002.jpg
case_images: fig2
case_images: The CT scan showed a tumor mass originating from the sternocleidomastoid muscle, most of which was in the Va and Vb levels of the neck, measuring 40 x 27 x 35 mm, and with a conglomerate of lymph nodes in the IV level measuring 26 x 22 x 23 mm (Figures 2(a)-2(c)).
case_images: Microscopic appearance of the samples. Hematoxylin & eosin (a). Cell cytoplasm showed dot-like positive staining for CK (b). Ki-67 stained 90% of tumor cells (c). Magnification x40.
case_images: CRIOT2024-8867131.003.jpg
case_images: PMC10904673_01_CRIOT2024-8867131.003.jpg
case_images: fig3
case_images: Ki-67 stained 90% of tumor cells (Figures 3(a)-3(c)).
case_images: Microscopic appearance of the samples. Tumor cells showed strong and diffuse positive staining for CD99 (a), FLI (b) and vimentin (c). Magnification x40.
case_images: CRIOT2024-8867131.004.jpg
case_images: PMC10904673_01_CRIOT2024-8867131.004.jpg
case_images: fig4
case_images: Tumor cells showed strong and diffuse positive staining for vimentin, CD99, and FLI (Figures 4(a)-4(c)).
case_images: Timeline figure depicting symptom onset, diagnostic workup, therapeutic interventions, complications, disease progression, and death of patients.
case_images: CRIOT2024-8867131.005.jpg
case_images: PMC10904673_01_CRIOT2024-8867131.005.jpg
case_images: fig5
case_images: The complete course of treatment for the patient from the onset of symptoms to the death outcome is given in Figure 5.